Clinical Trial Applications in China
Course
Online
*Indicative price
Original amount in USD:
$ 150
Description
-
Type
Workshop
-
Level
Advanced
-
Methodology
Online
-
Class hours
2h
-
Duration
1 Day
-
Start date
Different dates available
-
Virtual classes
Yes
Clinical trial application (CTA) is no longer like before, which the standard and requirement was much similar to a marketing authorization application.
Facilities
Location
Start date
Start date
Reviews
Subjects
- Marketing
- Clinical Trial
- Regulations
- Pharmaceutical
- Manufacturing
- Professional
- Medical training
- Courses
- Online Trainings
- Quality Assurance
Teachers and trainers (1)
Adam Fleming
Event Manager
Compliance4All is a professional trainings provider for the regulated industries. It offers professional trainings for regulatory compliance professionals and offers innovative strategic consulting and advice to a broad range of organizations. These services help them to be compliant with regulatory requirements. . Compliance4All has a panel of acclaimed Experts whose professional trainings help regulatory professionals and organizations in a number of ways and take them to their goal of meeting regulatory requirements.
Course programme
China FDA (CFDA), now renamed as CNDA, made a series of significant changes to the clinical trial regulations, issuing a large number of guidelines and opinions in Chinese.
As an important stage during medical products development, the regulation in terms of clinical trial in China is experiencing the huge change, reviewing the Clinical trial application (CTA) is no longer like before, which the standard and requirement was much similar to a marketing authorization application.
The reason is simple: to make it much easier for foreign companies to run clinical trials in China. China wants to attract foreign business and is keen to offer a business-friendly regulatory environment.
This webinar will:
- Summarise the key changes in the legislation
- Provide a comparison between the former and the new Clinical Trial Application processes
- Highlight the major benefits for foreign companies to run clinical trials in China
- Address the remaining challenges and pitfalls
- Suggest best practices when interacting with the regulatory authorities, such as the Center of Drug Evaluation (CDE) or the ethics committees
- Provide an opportunity to ask very specific questions about the CTA process for any type of drugs
Why should you Attend: Running clinical trials in China has become much easier. This is a highly attractive market for foreign companies, which has just become even more attractive. Opportunities and pitfalls abound.
Areas Covered in the Session:
- The new CTA process
- Timelines, requirements and relevant strategies
- Comparison with the previous regulations
- Communication strategies with the regulatory authorities
- Links to the new regulations and guidances
Who Will Benefit:
- Clinical Trial Managers
- Regulatory Affairs Professionals
- Medical Officers
Yingying Liu is a senior consultant working for Michor Consulting. She is an experienced Regulatory Affairs professional with a background in pharmaceutical science and technology. Yingying has worked on local and global projects for various blue-chip healthcare companies in China. She assisted a wide range of global clients obtaining clinical trial authorisations and bringing their products to market in China, and provided regulatory consultation to clients interested in registering or importing drugs or devices into China. In particular, she helped facilitate meetings and interactions with the China regulatory authorities.
Additional information
Clinical Trial Applications in China
*Indicative price
Original amount in USD:
$ 150